Erdafitinib FGFR — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateUrological CancersErdafitinib FGFRSCE Medical Oncology

A 60-year-old man with metastatic urothelial carcinoma has FGFR3 S249C mutation identified on NGS. He has progressed on gemcitabine-cisplatin and avelumab maintenance. What targeted therapy is now NICE-approved?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Erdafitinib (FGFR inhibitor)

Erdafitinib (pan-FGFR inhibitor) is NICE-approved (TA1062, THOR trial) for unresectable/metastatic urothelial cancer with susceptible FGFR3 genetic alterations after ≥1 prior line including a PD-1/PD-L1 inhibitor. The THOR trial showed significant OS benefit over chemotherapy. FGFR3 alterations (mutations and fusions) occur in approximately 15-20% of advanced urothelial cancer. Common FGFR3 mutations include S249C, Y373C, R248C. This represents a precision oncology approach in bladder cancer.

Reference: NICE TA1062 Erdafitinib; THOR Loriot et al NEJM 2023; ESMO 2024 Bladder Cancer